Role of Microvascular Endothelial Cells in Inflammation  by Swerlick, Robert A. & Lawley, Thomas J.
Role of Microvascular Endothelial Cells in
Inflammation
Robert A. Swerlick and Thomas J. Lawley
Endothelial cells are critical elements in the evolution of all types of cutaneous inflammation. They participate through
the synthesis and secretion of pro-inflammatory cytokines, including interleukin 1 (IL-1), IL-6, and IL-8, as well as
M-CSF, G-CSF, GM-CSF, groa, and MCP. They also express a series of cell-surface proteins and glycoproteins known
as cell adhesion molecules that allow circulating leukocytes to bind to endothelial cells and allow endothelial cells
to bind to matrix proteins. The regulated expression of these molecules, including those in the integrin, immuno-
globulin gene, and selectin families, allows for the precise trafficking of circulating leukocytes to sites of inflam-
mation, injury, or immunologic stimulation in the skin. Furthermore, emerging evidence clearly indicates that selected
differences exist between endothelial cells of the microvasculature and those that line large blood vessels. These
include differences in secreted products, differences in the expression of cell adhesion molecules, and differences in
cytokine-induced regulation of commonly expressed cell adhesion molecules, among others. Thus, a precise
delineation of the biology of cutaneous microvascular endothelial cells is important to our understanding of
cutaneous inflammation. J Invest Dermatol 100:111S–115S, 1993
Endothelial cells have become the object of intense interest by a
wide variety of biologists. They are strategically located between
the intravascular elements and the parenchyma of every organ.
Therefore, it seems logical to assume that, in addition to forming
this crucial boundary, they might play a variety of other important
physiologic roles. However, it was not until a series of break-
throughs occurred that allowed for the isolation and subsequent
culture of endothelial cells in vitro that substantive questions
could be addressed in a stepwise fashion. Most of what we know
about the structure and function of human endothelial cells stems
from studies of human umbilical vein endothelial cells (HUVEC).
These cells are relatively easily isolated and inexpensively
cultured and have proved to be extremely useful. Studies using
them have provided persuasive evidence that endothelial cells
function not only in providing a nonthrombogenic surface to the
intravascular compartment but also in a host of other critical
areas. These include wound healing, angiogenesis, production of
clotting factors, tumor metastasis, cytokine production, leukocyte
trafficking, vascular tone, and many others. Thus, far from being
either passive elements in physiologic processes or innocent
bystanders in pathologic processes, they are active in the
creation, modulation, and probably termination of inflammation.
They clearly have the capabilities to participate integrally in the
precise localization of the inflammatory response. The details of
how endothelial cells participate in these processes are not yet
completely understood but will form the basis of much of
this review. Finally, increasing evidence also indicates that endo-
thelial cells derived from different types of vessels are phenoty-
pically and functionally different. Thus, although many valuable
insights have been obtained by in vitro studies of human
large-vessel endothelial cells, most physiologic and pathophysio-
logic events take place at the level of the microvasculature.
Studies using human dermal microvascular endothelial cells
(HDMEC) have revealed a number of important differences
between large- and small-vessel endothelial cells, including their
tube-forming ability, prostaglandin secretory profile, growth
requirements in vitro, and, perhaps most important, the expres-
sion, regulation, and function of cell adhesion molecules on their
surface.
CYTOKINES AND LEUKOCYTE CHEMOTACTIC
FACTORS PRODUCED BY ENDOTHELIAL CELLS
Endothelial cells are known to produce a series of factors that are
capable of inducing inflammation and recruiting leukocytes.
These include three cytokines, IL-1 [1], IL-6 [2,3], and IL-8 [4];
three colony-stimulating factors, G-CSF, M-CSF, and GM-CSF
(1,2); and two chemotactic factors, groa and MCP [5]. IL-1 has
effects on hemostasis, vascular tone, circulating leukocytes, and
endothelial cells themselves. IL-1 appears to induce platelet-
activating factor synthesis [6] by endothelial cells as well as
production of prostaglandin I2 (PGI2) [7] and nitric oxide [8]. It
also activates resting T cells, is a T- and B-cell chemoattractant,
and induces proliferation of B cells [9]. Moreover, IL-1 has
numerous effects on human endothelial cells, including the
induction of production of cytokines, colony-stimulating factors,
and chemotactic factors [1,2], as well as induction or upregula-
tion of cell adhesion molecule expression, including intercellular
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adhesion molecule 1 (ICAM-1), vascular adhesion molecule
1 (VCAM-1), and E-selectin [10–12] (see below).
IL-6, which is a potent growth- or differentiation-stimulating
factor for B cells, does not appear to have these effects on normal
endothelial cells, nor does it influence cell adhesion molecule
expression [3]. It does appear to be a growth factor for Kaposi
sarcoma cells and may be critical in the evolution of this vascular
neoplasm [13].
IL-8 and groa, produced by endothelial cells in response to
IL-1, TNFa, and LPS, are chemotactic for polymorphonuclear
neutrophils (PMN) [4]. There is controversy regarding the effects
of IL-8 on PMN-endothelial cell interactions. Reports indicating
that IL-8 enhanced adhesiveness of PMN to endothelial cells have
been contradicted by work indicating exactly the opposite
[14,15]. Thus, the role of locally produced IL-8 in inflammation
is not entirely clear.
The role of colony-stimulating factors produced by endothelial
cells in the genesis or evolution of inflammation is currently
unknown.
CELL ADHESION MOLECULES EXPRESSED
BY ENDOTHELIAL CELLS
Cell adhesion molecules are cell-surface proteins, glycoproteins,
or lectins that mediate cell-cell or cell-matrix binding. They play
critical roles in acute and chronic inflammation, wound healing,
tumor metastasis, immune mechanisms, hemostasis, and throm-
bosis. There are at least five families of cell adhesion molecules.
They are 1) the immunoglobulin gene superfamily, 2) the selectin
family, 3) the integrin family, 4) the cadherin family, and 5) the
cartilage link protein family. Endothelial cells express molecules
that are members of all of these families, and these cell-surface
markers are critical to the proper functioning of endothelial cells
during inflammation (Table I).
The immunoglobulin gene superfamily consists of a large
number of proteins whose overall structure bears resemblance to
immunoglobulin [16]. Those that are known to exist or to be
inducible on endothelial cells include ICAM-1 (CD54), ICAM-2,
CD31, VCAM-1, and major histocompatibility complex class I
and class II, and CD58 (lymphocyte function-associated antigen 3
[LFA-3]). ICAM-1 is of particular interest, because it has been
shown to be an important molecule that mediates the firm
binding of a variety of leukocytes to endothelial cells via its
interaction with LFA-1 on the circulating white blood cells [17].
ICAM-1 is constitutively expressed on endothelial cells, and
its expression can be markedly increased by exposure of the
endothelial cells to cytokines, including IL-la, tumor necrosis
factor alpha (TNFa), and interferon gamma (IFNg) [12,18]. ICAM-2
appears to be constitutively expressed by endothelial cells at
high levels, but its expression is not further augmented by
pro-inflammatory cytokines [19].
The selectin family of cell adhesion molecules consists of a
series of glycoproteins expressed by leukocytes, platelets, and
endothelial cells [20]. They are integral membrane elements
that have N-terminal C-type lectin domains, an EGF-like domain,
and a series of complement binding protein-like domains.
These molecules are termed L-selection (LECAM-1), P-selectin
(GMP-140 [CD62]), and E-selectin (ELAM-1). Two of these
molecules, P-selectin and E-selectin, are expressed by endothelial
cells and seem to be critically important in inflammation.
P-selectin is not constitutively expressed by endothelial cells but
can be rapidly (within minutes) induced by histamine or thrombin
[21]. P-selectin is important in mediating the initial phases of
binding of PMN to endothelial cells [21] and may also mediate the
binding of specific T-cell subsets to endothelial cells [22,23].
E-selectin is a 110-kD glycoprotein that is also not constitu-
tively expressed by endothelial cells, but may be induced within
hours by a variety of pro-inflammatory cytokines on either large-
or small-vessel endothelial cells in vitro [24]. Although it was
originally postulated that E-selectin bound primarily neutrophils,
was transiently expressed in vivo, and primarily mediated
leukocyte binding in acute inflammation, each of these observa-
tions has now been called into question. E-selectin has been
shown to bind memory T lymphocytes in vitro [25] and appears to
specifically bind HECA-452 expressing lymphocytes, a subset of
skin homing T cells [26]. In fact, several studies indicate that
E-selectin is persistently expressed in certain forms of chronic
cutaneous inflammation [27], that memory T cells preferentially
bind to E-selectin [25], and that E-selectin may function as a
homing molecule for these cells to traffic to skin [26].
The integrins are heterodimers consisting of noncovalently
associated a and b subunits [28,29], They mediate both cell-
matrix and cell-cell binding. The integrins are usually subclassi-
fied according to the structure of their b chains into the b1, b2,
b3, etc., subfamilies. Currently there are up to eight subfamilies
recognized. Most of the members of the b1 subfamily are
responsible for binding cells to matrix proteins such as collagen,
laminin, and fibronectin. The exception is a4b1 (also known as
VLA-4), which recognizes an alternatively spliced form of fibro-
nectin. a4b1 is also the ligand on leukocytes for an endothelial
cell adhesion molecule known as VCAM-1. Emerging evidence
clearly indicates that integrins on endothelial cells can be upregulated
and downregulated by a variety of cytokines (see below).
ENDOTHELIAL CELL HETEROGENEITY
The development of in vitro culture systems that allowed for the
propagation of human endothelial cells in tissue culture was a
critical step in expanding our understanding of endothelial cell
biology. However, the observations made utilizing these techni-
ques were made almost exclusively on large-vessel-derived
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endothelial cells. In vivo histologic studies provided evidence
that small-vessel endothelial cells were phenotypically different
from large-vessel endothelial cells [30,31], but difficulties in
isolation of human microvascular endothelial cells limited the
scope of in vitro studies of these cells.
In the 1980s, three groups developed techniques that
allowed for the isolation and culture of microvascular endothelial
cells from human skin [32–34]. The availability of these cells
permitted studies that confirmed the validity of previous in vivo
observations that microvascular endothelial ceils were phenoty-
pically distinct from large-vessel endothelial cells [18,35,36],
Furthermore, the ability to culture and study these cells in vitro
provided evidence that microvascular endothelial cells were
also biochemically [37] and functionally different [38] as well.
Human dermal microvascular endothelial cells (HDMEC) are
much more fastidious in their growth requirements than large-
vessel endothelial cells, requiring human serum for optimal
growth [34]. Furthermore, they demonstrate marked differences
in prostaglandin secretion, producing primarily prostaglandin
PGF2a in contrast to PGI2 characteristic of large-vessel endo-
thelial cells [37].
The HDMEC phenotype is similar to the phenotype of HUVEC,
but does show distinct and important differences. Like HUVEC,
HDMEC express von Willebrand factor (vWf, factor VIII-
associated antigen) and are able to take up acetylated low-
density lipoprotein, features common to virtually all endothelial
cells. Additionally, both HUVEC and HDMEC express CD 31
(PECAM), CD 9, CD 13, endoglin, and cell-surface epitopes
identified by monoclonal antibodies PAL-E and EN-4 [39]. Both
HDMEC and HUVEC also constitutively express MHC class I and
can be induced to express MHC class II after stimulation with
interferon gamma [18].
The most notable differences in endothelial cell phenotype
between HDMEC and HUVEC are related to differences in cell
adhesion molecule expression. Both HDMEC and HUVEC
express ICAM-1, but the baseline level of ICAM-1 expressed on
HDMEC is substantially higher than that seen on HUVEC [18].
However, after cytokine stimulation, both HDMEC and HUVEC
express comparable levels of ICAM-1. HDMEC express CD36, an
88-kD glycoprotein that plays an important role in the patho-
genesis of vaso-occlusive events characteristic of malaria [35]. In
contrast, HUVEC do not express CD36 in vivo or in vitro, nor can
it be induced by a variety of pro-inflammatory cytokines.
Additionally, HDMEC express neural cell adhesion molecule
(NCAM) whereas large-vessel endothelial cells do not [36].
Cultured HUVEC highly express CD44, an adhesion molecule
that may play a role in lymphocyte homing, whereas HDMEC
only weakly express CD44 [40].
VCAM-1 can be induced on both HDMEC or HUVEC, but the
regulation of VCAM-1 is distinctly different on the two cell types.
VCAM-1 can be induced on HUVEC in vitro by either IL-1, TNF,
or IL-4 [41–43]. In contrast, only TNF is capable of inducing
VCAM-1 on HDMEC in vitro [43]. Furthermore, examination of
cutaneous inflammation suggests that VCAM-1 may be regulated
similarly in vivo. Intradermal injections of IL-1 resulted in marked
induction of E-selectin, but only scant VCAM-1 induction [44].
Furthermore, UVB-induced cutaneous inflammation (a known
in-ducer of IL-1 production by keratinocytes) may result in intense
E-selectin expression that may persist up to 1 week in the absence
of VCAM-1 expression [45]. Therefore, the differential regulation
of VCAM-1 on small- versus large-vessel endothelial cells appears
to occur both in vivo and in vitro, which may have important
implications with regard to leukocyte trafficking.
The functional consequences of differences in CAM regulation
and expression are now becoming apparent. Recently, studies
have demonstrated that cytokine stimulation of HUVEC increased
the binding of selected tumor cell lines [46,47]. This cytokine-
induced increase in tumor-cell binding is potentially an important
mechanism by which circulating tumor cells may bind to
endothelium and metastasize to a site distant from the primary
tumor. Two distinct pathways have been characterized and, not
surprisingly, the adherence mechanisms utilize two pathways
previously characterized in the binding of leukocytes to
endothelial cells. Selected melanoma cell lines that express
VLA-4 are capable of binding to VCAM-1 -expressing endothelial
cells, and certain epithelial tumors that express the sialyl Lewis X
epitope are capable of binding to E-selectin – expressing
endothelial cells [46]. Similar studies have been done with
HDMEC and demonstrate that although cytokine stimulation of
HDMEC results in increased melanoma cell binding, the
increases in adherence are independent of the expression of
VCAM-1 or E-selectin [38]. These data suggest that additional, as
of yet undefined, CAMs exist, which may explain the localization
of tumor metastases to specific vascular beds.
CD36 is a multifunctional adherence protein that has been
shown to bind a variety of matrix proteins. In vitro, endothelial
cells expressing CD36 are targets for the binding of erythrocytes
that have been infected with Plasmodium falciparum [35] and
infection of erythrocytes with some strains of P. falciparum leads
to adherence to endothelial cells via an ICAM-1 -dependent
pathway as well [48]. The binding of red blood cells to
microvascular endothelial cells may result in microvascular
occlusion and infarction. The differential expression of CD36
on microvascular endothelial cells as well as their higher basal
expression of ICAM-1 would likely increase their affinity for
P. falciparum -infected erythrocytes.
Within the context of a number of physiologic and pathologic
processes, endothelial cells are called upon to form new vessels.
An interesting in vitro observation by Maciag et al demonstrated
that endothelial cells in culture were capable of forming vascular
tube-like structures in vitro [49]. However, this occurred with
large-vessel endothelial cells in vitro only after many weeks in
culture in the absence of growth factors. Subsequently, Kubota
et al found that HDMEC formed tubes much more rapidly in vitro
[34]. Furthermore, both HDMEC and HUVEC could be induced
to form capillary-like structures within hours if they were placed
on a reconstituted basement membrane-like structure derived
from proteins made by the mouse EHS sarcoma.
The differences in the ability of HDMEC and HUVEC to form
tube structures in vitro suggested that the cell-surface proteins
involved in matrix recognition and binding may be differentially
expressed and regulated. Recent studies in our laboratory and
others have clearly confirmed this speculation. Microvascular
endothelial cells express the a1b1 (VLA-1) integrin in vivo and
in vitro, whereas this integrin is only weakly expressed on large –
vessel – derived endothelial cells [50,51]. The unstimulated
expression of other integrin complexes is similar on HDMEC and
HUVEC. Both cell types express a2b1, a3b1, a5b1, a6b1, and
avb3 [51,52]. However, the expression of certain integrin chains
is regulated very differently on large- and small-vessel endothelial
cells. Basic fibroblast growth factor stimulation of HDMEC results
in increases in the expression of the avb3 complex associated
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with marked changes in cell morphology [53,54]. The changes in
integrin expression are not limited to the avb3 complex, with
bFGF stimulation also leading to decreased expression of a3b1
[51,53] and a6b1 (unpublished observation). Interestingly, FGF is
known to be a potent stimulator of endothelial cell migration
[55], and the decreases in expression of a3b1, an integrin known
to be important in interaction with basement membrane proteins,
may be critical in allowing endothelial cells to detach and
migrate [56]. However, bFGF does not change either integrin
expression or the morphology of HUVEC [49]. Given these
differences in response to bFGF, one may speculate that the
differential effects of bFGF on vascular endothelial cells may be
important in the genesis and evolution of neovascularization.
Endothelial cells are clearly active participants in the initiation
and evolution of cutaneous inflammation. They act on and are
acted on by infiltrating leukocytes via the expression of specific
adhesion molecules and by the secretion of vasoactive and pro-
inflammatory cytokines. Additionally, the ability to study
endothelial cells from different organs and from different caliber
vessels has demonstrated phenotypic, functional, and biochem-
ical differences between endothelial cells derived from different
sites and these differences appear to relate directly to differences
in endothelial cells function in vivo. Understanding these
functions and differences will likely lead to improvement in our
ability to influence cutaneous inflammation and wound healing.
Models of cutaneous vasculitis have generally failed to
consider that endothelial cells could become active participants
in the development of vasculitis. The widespread view that
endothelial cells serve as a passive target of immunologic injury
and that clinical disease simply develops after overwhelming
immunologic attack is clearly inadequate given the overwhelm-
ing evidence that endothelial cells are critical elements in the
initiation and regulation of cutaneous inflammation. Newer
models must take into consideration the endothelial cell
elaboration of and response to pro-inflammatory cytokines as
well as endothelial cell interactions with leukocytes via regulated
adhesion molecule expression in order to more fully define the
evolution of cutaneous vasculitis.
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